Japan’s investment in India: post covid-19 investment opportunities in pharmaceuticals-Reference-Cited by-同舟云学术

Japan’s investment in India: post covid-19 investment opportunities in pharmaceuticals

Published:2021-03-23 Issue: Volume: Page:1-15
ISSN:1918-6444
Container-title:Transnational Corporations Review
language:en
Short-container-title:Transnational Corporations Review

Author:

Kumari Madhuri¹,Bharti Nalin¹,Kamiike Atsuko²

Affiliation:

1. Department of HSS, IIT Patna, India

2. Faculty of Commerce, Chuo Gakuin University, Japan

Publisher

Informa UK Limited

Subject

Strategy and Management,Economics and Econometrics,Finance,Business and International Management

Link

https://www.tandfonline.com/doi/pdf/10.1080/19186444.2021.1898860

Reference44 articles.

1. Banarjea, A. (2020, November). India’s trade deficit in October narrows to $8.78bn, exports fall 5%. Live Mint.

2. Branch, P. & Fuji, R. (2017). How to navigate the challenging Japanese pharma market. L.E.K Consulting. Retrieved from https://www.lek.com/sites/default/files/insights/pdf-attachments/How_to_Navigate_Japan_Pharma_Market_LEK_Special_Report.pdf

3. CEPA. (2011). India-Japan CEPA. Retrieved from https://commerce.gov.in/writereaddata/pdf_download/IJCEPA_Basic_Agreement.pdf

4. Indian pharma threatened by COVID-19 shutdowns in China

5. Daiichi Sankyo. (2016). The outcome of arbitration proceeding with certain former shareholders of Ranbaxy. Retrieved from https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006438.html

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 impact on India: Challenges and Opportunities;BRICS Journal of Economics;2023-03-31

2. Access to Medicines and Medical Equipment during COVID-19: Searching Compatibility between the WTO and the WHO;India Quarterly: A Journal of International Affairs;2022-01-05